Giuseppe
Emeritus
Using Surveillance to Evaluate Influenza Vaccine Effectiveness - Chicago Journals - The Journal of Infectious Diseases
The Journal of Infectious Diseases 2009;199:000?000
? 2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2009/19902-00XX$15.00
DOI: 10.1086/595863
EDITORIAL COMMENTARY [Excerpt]
Using Surveillance to Evaluate Influenza Vaccine Effectiveness
Lisa A. Jackson
Group Health Center for Health Studies, Seattle, Washington
Received 8 October 2008; accepted 8 October 2008; electronically published 16 December 2008.
* (See the article by Skowronski et al., on pages XXX?XX, and the article by Belongia et al., on pages XXX?XX.)
Reprints or correspondence: Lisa A. Jackson, MD, MPH, Group Health Center for Health Studies, 1730 Minor Ave., Ste. 1600, Seattle, WA 98101 (Jackson.L@ghc.org).
Influenza vaccine is unique in that it is reformulated annually to include the viral strains predicted to be the most likely to circulate during the coming influenza season.
During years when the predominant circulating strain is antigenically dissimilar from the corresponding vaccine strain, the effectiveness of trivalent inactivated influenza vaccine (TIV) may be diminished, but this variation is unpredictable, and during those years the benefit derived from TIV is difficult to estimate reliably.
The question of vaccine effectiveness (VE) against mismatched strains is important, because in the United States the influenza A/H3N2 vaccine strain has represented fewer than 25% of the circulating H3N2 strains during 4 of the past 10 years, and for B strains there has been a lineage-level mismatch between the vaccine and circulating strains during 4 of the 7 years since 2001, when both B lineages (Victoria and Yamagata) have circulated in North America.
(...)
<cite cite="http://www.journals.uchicago.edu/doi/full/10.1086/595863">Chicago Journals - The Journal of Infectious Diseases</cite>? 2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2009/19902-00XX$15.00
DOI: 10.1086/595863
EDITORIAL COMMENTARY [Excerpt]
Using Surveillance to Evaluate Influenza Vaccine Effectiveness
Lisa A. Jackson
Group Health Center for Health Studies, Seattle, Washington
Received 8 October 2008; accepted 8 October 2008; electronically published 16 December 2008.
* (See the article by Skowronski et al., on pages XXX?XX, and the article by Belongia et al., on pages XXX?XX.)
Reprints or correspondence: Lisa A. Jackson, MD, MPH, Group Health Center for Health Studies, 1730 Minor Ave., Ste. 1600, Seattle, WA 98101 (Jackson.L@ghc.org).
Influenza vaccine is unique in that it is reformulated annually to include the viral strains predicted to be the most likely to circulate during the coming influenza season.
During years when the predominant circulating strain is antigenically dissimilar from the corresponding vaccine strain, the effectiveness of trivalent inactivated influenza vaccine (TIV) may be diminished, but this variation is unpredictable, and during those years the benefit derived from TIV is difficult to estimate reliably.
The question of vaccine effectiveness (VE) against mismatched strains is important, because in the United States the influenza A/H3N2 vaccine strain has represented fewer than 25% of the circulating H3N2 strains during 4 of the past 10 years, and for B strains there has been a lineage-level mismatch between the vaccine and circulating strains during 4 of the 7 years since 2001, when both B lineages (Victoria and Yamagata) have circulated in North America.
(...)